Study to evaluate the possibility of using different doses of brain radiotherapy according to the response of chemotherapy in a rare brain tumour.

Study to evaluate the feasibility of response adapted whole brain radiotherapy after methotrexate based chemotherapy in patients of newly diagnosed primary CNS lymphoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/10/006268

Enrollment

Registered

2015-10-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Biopsy proven, newly diagnosed, immunocompetent untreated primary CNS lymphoma patients

Interventions

Intervention1: Reduced dose whole brain radiotherapy: Reduced dose 23.4gy/13#/2.5weeks whole brain radiotherapy to those achieving complete response to methotrexate based chemotherapy Intervention2: I

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed, not received any treatment for primary cns lymphoma previously, with performance status(PS) ECOG 0-3, biopsy proven disease, immunocompetent

Exclusion criteria

Exclusion criteria: Any comorbidity that compromises chemo-radiotherapy treatment

Design outcomes

Primary

Measure	Time frame
Response rate, Progression free survivalTimepoint: 6 months, 2 years	—

Secondary

Measure	Time frame
Overall survival, toxiciy profile, Neuropsychological profile, Pathological correlation with treatment outcomesTimepoint: 2 years	—

Countries

India

Contacts

Public ContactNarayan Adhikari

All India Institute of Medical Sciences

dr_ahitagni@yahoo.co.in9013590854

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 7, 2026